Methods of preventing or treating flavivirus virus infections and methods of inhibiting the entry of flvivirus, enterovirus or lentivirus into host cells
View Patent ↗A method of preventing or treating a subject suffering from a flavivirus infection by administering an effective amount of berbamine or its analogue to the subject, berbamine has a structure of Formula (I), wherein the flavivirus infection is caused by Japanese encephalitis virus, Zika virus or Dengue virus. A method of inhibiting the entry of a flavivirus, an enterovirus and/or a lentivirus into host cells includes contacting the host cells with an effective amount of berbamine of its analogue, berbamine has a structure of Formula (I), wherein the flavivirus is Japanese encephalitis virus, Zika virus or Dengue virus.
1. A method of preventing or treating a subject suffering from a flavivirus infection by administering an effective amount of berbamine or its analogue to the subject, wherein berbamine has a structure of Formula (I):
wherein the flavivirus infection is caused by Japanese encephalitis virus, Zika virus or Dengue virus; and
wherein berbamine or its analogue is administered in combination with a compound selected from the group consisting of the following compounds and a derivative thereof:
2. The method of claim 1 , wherein the analogue of berbamine has a structure of Formula (II), (III), or (IV):
3. The method of claim 2 , wherein the analogue of berbamine has a structure of Formula (IIb), (Mb) or (IVb):
4. The method of claim 1 , wherein berbamine or its analogue further inhibits the entry of an enterovirus and/or a lentivirus in host cells of the subject.
5. The method of claim 1 , wherein berbamine or its analogue is administered to the subject by a route selected from a group consisting of oral delivery, intravenous delivery, intradermal delivery, intraperitoneal delivery and intramuscular delivery.
6. The method of claim 1 , wherein the subject is a mammal and the berbamine or its analogue is administered to the subject at a dose of about 20 mg/kg to about 50 mg/kg.
7. The method of claim 1 , wherein the subject is human and berbamine or its analogue is administered to the subject at a dose of about 20 mg/kg to about 50 mg/kg.
8. The method of claim 4 , wherein the enterovirus is EV-A71.
9. The method of claim 4 , wherein the lentivirus encodes histone B-RFP.